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Abstract
Purpose There is limited high-quality evidence on quality of life, anxiety, and depressive symptoms in breast cancer survivors
and women with no history of cancer. We aimed to address this by comparing patient-reported outcomes between breast cancer
survivors and women with no history of breast cancer.
Methods Breast cancer survivors and women with no prior cancer were selected from the UK Clinical Practice Research
Datalink GOLD primary care database, which includes population-based primary care electronic health record data. Breast
cancer survivors and controls were frequency matched by age and primary care practice. Outcomes were assessed with validated
instruments via postal questionnaire. Linear and logistic regression models were fitted to estimate adjusted associations between
breast cancer survivorship and outcomes.
Results A total of 356 breast cancer survivors (8.1 years post diagnosis) and 252 women with no prior cancer participated in the
study. Compared with non-cancer controls, breast cancer survivors had poorer QoL in the domains of cognitive problems
(adjusted β (aβ) = 1.4, p = 0.01), sexual function (aβ= 1.7, p = 0.02) and fatigue (aβ= 1.3, p = 0.01), but no difference in
negative feelings, positive feelings, pain, or social avoidance. Breast cancer survivors had higher odds of borderline-probable
anxiety (score ≥ 8) (adjusted OR = 1.47, 95%CI:1.15–1.87), but no differences in depression. Advanced stage at diagnosis and
chemotherapy treatment were associated with poorer QoL.
Conclusions Compared with women with no history of cancer, breast cancer survivors report more problems with cognition,
sexual function, fatigue, and anxiety, particularly where their cancer was advanced and/or treated with chemotherapy.
Implications for Cancer Survivors Breast cancer survivors with more advanced disease and/or treated with chemotherapy should be
closely monitored and, when possible, offered evidence-based intervention for fatigue, cognitive dysfunction, and sexual problems.
Keywords Breast cancer . Anxiety . Depression . Quality of life . United Kingdom
Introduction
Millions of women worldwide are living beyond breast can-
cer, including over 2.7 million in the USA and 500,000 in the
United Kingdom (UK) [1, 2]. Numbers are projected to rise
further due to increasing trends in both incidence and survival
[2], which demands for a better understanding of the long-
term consequences of having a history of breast cancer.
Many women undergoing treatment for recently diagnosed
breast cancer report clinically relevant symptoms of anxiety
and/or depression [3, 4], and impairments for virtually all
domains of quality of life (QoL) [5, 6]. Longitudinal studies
have shown that mental health symptoms and QoL scores tend
to improve over time, with many breast cancer survivors
reaching similar levels to those of the general population
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around 1 year after the diagnosis [7, 8]. However, specific
groups of breast cancer survivors appear to continue to have
poorer QoL, anxiety, and depression in the long-term [9].
Factors that have been associated with poorer mental health
and quality of life include younger age at diagnosis [10, 11],
lower socio-economic status [12], persistent fatigue [13],
lymphedema or arm symptoms [14, 15], and having had che-
motherapy [16, 17].
The UK National Cancer Research Institute identified sev-
eral areas related to psychological wellbeing and QoL in the
top 20 priorities for patients living with and beyond cancer
[18], but research on the QoL of breast cancer survivors in the
UK is scarce [19–21]. A large study on the QoL of breast,
colorectal, and prostate cancer survivors (5 to 16 years post
diagnosis) reported that a proportion of cancer survivors in the
UKmay have poorer long-termQoL and need of support [21],
and highlighted the need to identify these patients’
characteristics.
This study aimed to quantify patient-reported outcomes of
QoL, anxiety, and depressive symptoms, in breast cancer sur-
vivors (> 1 year) compared with women with no prior history
of cancer, and investigate socio-demographic and clinical de-
terminants of QoL and mental health among breast cancer
survivors.
Methods
Study design, sample size, and sampling frame
We designed a matched cross-sectional study including breast
cancer survivors and a comparison group of women with no
prior cancer. Between October 2018 and August 2019, we
invited all primary care practices contributing with data to
the Clinical Practice Research Datalink (CPRD) General
Practitioners Online Database (GOLD) to participate in the
study. CPRD is a UK government research service that col-
lects, processes, and releases anonymised electronic health
records from patients attending the UK National Health
Service [22]. Patients registered with primary care practices
that accepted to participate were potentially eligible for the
study (see details below).
Patient eligibility criteria
Inclusion criteria for the group of breast cancer survivors were
as follows: (1) a diagnosis of invasive breast cancer (all stages)
at least 1 year before, (2) aged 18–80 years, and (3) at least
1 year of follow-up in CPRD prior to the diagnosis (to ensure
that the cancer was incident). For the comparison group, in-
clusion criteria were (1) no history of cancer (except non-
melanoma skin cancer), (2) age 18–80 years, and (3) at least
2 years of follow-up data in CPRD (since we required 1 year
of follow-up before and after cancer in the exposed group).
Exclusion criteria for both groups were (1) inability to com-
plete a self-reported questionnaire (e.g. due to dementia) and
(2) having had another (non-breast) cancer or having been
treated for a non-invasive breast tumour.
Patient selection and recruitment
The CPRD GOLD primary care database was used to identify
all breast cancer survivors from the participating practices.
Women in the comparison group were randomly selected
from the same practice, and frequency-matched on age to
the breast cancer survivors in that practice. Initially controls
werematched to breast cancer survivors with a ratio of 1:1, but
this was revised early during recruitment to 2:1 due to ~ 50%
lower response among controls. General practitioners
reviewed the records of potentially eligible patients, applied
inclusion/exclusion criteria (vide above), and sent the study
materials to the eligible patients’ addresses with a pre-paid
envelope to return the questionnaires. Patients were recruited
between January and October 2019.
Patient-reported outcomes
QoL was assessed with the Quality of Life in Adult Cancer
Survivors (QLACS) scale [23]. This tool includes 47 items
referring to the previous 4 weeks, divided in 7 generic do-
mains (i.e. negative feelings, positive feelings, cognitive prob-
lems, pain, sexual function/interest, energy/fatigue, and avoid-
ance) and 5 cancer-specific domains (i.e. financial problems,
benefits of cancer, distress-family, appearance, distress-recur-
rence). Women in the comparison group replied to the generic
domains only.
Anxiety and depressive symptoms were measured with the
Hospital Anxiety and Depression Scale (HADS) [24]. This is
a 14-item self-reported screening tool for anxiety and depres-
sive symptoms in the past week [24]. The recommended cut-
offs were used to categorise patients as non-case (scores 0–7),
borderline (scores 8–10), and probable case (scores 11–21)
[24].
Socio-demographic and clinical information
All women were asked to complete a questionnaire with in-
formation on education, ethnicity, and social support through
proxy of living arrangements (alone/not alone). Breast cancer
survivors provided information about cancer treatments, stage
of the disease at diagnosis, menopausal status, and status of
the disease (active/remission). Patient-reported information
was linked to the patient’s electronic health record and
practice-postcode quintile of Index of Multiple Deprivation
(IMD).
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Statistical analysis
Descriptive QoL and anxiety and depressive symptoms
We calculated QoL-domain scores for each patient. When
there was one missing response for an item within a domain,
we imputed the mean of the responses to the other items with-
in that domain; if ≥ 2 responses were missing, the domain
score was not calculated [25]. The summary score for generic
domains of QoL was calculated by the sum of the domain
scores, with reverse scoring for positive feelings. For the sum-
mary cancer specific domain, we added all domain scores
except ‘benefits from cancer’. We calculated mean scores
for each sub-scale of HADS. When there were three or fewer
items missing per sub-scale, we imputed the average of the
responses in that subscale [26]. Scores were summarised for
each group using means and measures of dispersion.
Comparison of outcomes between breast cancer survivors
and controls
We fitted domain-specific multiple linear regression models,
using the domain scores as the dependent variable and the
following independent variables: patient group (exposed vs.
control), age group (< 60, 60–69, ≥ 70 years), higher educa-
tion degree (yes/no), and quintile of IMD. Interactions be-
tween the exposure and socio-demographic variables were
tested but not included in the final models as these were not
significant.
Outcome-specific logistic regression models were used to
estimate the association between breast cancer survivorship
and probable anxiety (HADS-A ≥ 11) and depression
(HADS-D ≥ 11). Models were further adjusted for age (< 60,
60–69, ≥ 70 years), higher education degree (yes/no), and
quintile of IMD. In an a priori defined sensitivity analysis
(see study protocol, Supplementary file), we used a lower
cut-off (HADS-A ≥ 8; HADS-D ≥ 8) for caseness, as the stan-
dard cut-off ≥ 11 was found to have low sensitivity (50%,
95%CI 27% to 73%) to detect cases of depression in this
patient population [27].
For all models, robust standard errors were computed to
account for patient clustering by primary care practice, and
regression coefficients (β) and 95% confidence intervals
(95%CI) were reported.
Socio-demographic and clinical determinants of QoL,
and anxiety and depressive symptoms in breast cancer
survivors
We used linear regression models to assess the impact of
socio-demographic, clinical, and treatment factors on the ge-
neric and cancer-specific domains of QoL, and HADS-sub-
scales. Socio-demographic variables were age (< 60, 60–69,
and ≥ 70 years), practice postcode-linked IMD quintile, higher
education degree (yes/no), and living arrangements (alone/not
alone). Clinical variables were type of surgery (breast con-
serving/mastectomy), breast reconstruction (yes/no), stage at
diagnosis (localised/lymph node or distant metastases), remis-
sion status (yes/no), menopausal status (pre/postmenopausal),
time since diagnosis (1–5, 5–10, and > 10 years), and treat-
ment with chemotherapy (yes/no), radiotherapy (yes/no), hor-
mone therapy (yes/no), and immunotherapy (yes/no). For age
at diagnosis, education, stage at diagnosis, and exposure to
chemotherapy, we fitted models adjusted for socio-
demographic factors only (age, education, IMD quintile and
country), as well as models adjusted for chemotherapy (yes/
no) and stage at diagnosis (early/advanced). The regression
coefficients (β) and respective 95%CIs were reported.
Results
A total of 356 breast cancer survivors and 252 women with no
history of cancer, from 40 primary care practices in the UK,
participated in the study (Fig. 1). Participants tended to live in
more affluent areas compared with non-participants
(Supplementary Table 1). Mean age was 64.8 years among
breast cancer survivors (standard deviation (SD) = 9.0; range
34–81) and 65.5 years in the non-cancer comparison group
(SD = 9.4; range 36–81). In both groups, a quarter of the
women had a higher education degree (Table 1). Breast cancer
survivors were on average 8.1 years post diagnosis (SD = 4.6;
range 2–26). About 99% of the breast cancer survivors had
surgery (35% mastectomy), 80% radiotherapy, 49% hormone
therapy, and 41% chemotherapy. Most women had been di-
agnosed with localised (54.4%) or locally invasive disease
(43.3%). Table 2 shows the mean scores for QoL domains
in the two groups.
QoL, anxiety, and depressive symptoms in breast
cancer survivors compared with women with no
history of cancer
After adjusting for age, education, and deprivation, breast
cancer survivors had poorer QoL compared with controls for
cognitive problems (adjusted β (aβ) = 1.4; 95%CI 0.4–2.3,
p=0.01), sexual function (aβ = 1.7; 95%CI 0.4–3.1, p=0.02),
and fatigue (aβ = 1.3; 95%CI 0.4–2.2, p=0.01) (Table 3); dif-
ferences for other domains were compatible with chance var-
iation. Compared with controls, breast cancer survivors treat-
ed with chemotherapy reported significantly poorer overall
quality of life, with more negative feelings, cognitive prob-
lems, sexual dysfunction, fatigue, and anxiety (Table 3).
Similar results were found for breast cancer survivors diag-
nosed with more advanced disease, except for anxiety scores
that were not significantly different between groups.
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Table 1 Characteristics of the study participants*§
No history of cancer (N = 252) Breast cancer survivors (N = 356)
N % N %
Age at completion of questionnaire
34–59 years 71 28.1 103 28.9
60–69 years 80 31.7 130 36.5
≥ 70 years 101 40.1 123 34.6
Highest education level (schooling years)
Up to GCSEs, O levels, or equivalent (Up to 11 years) 78 31.0 127 35.7
A levels or equivalent (13 years) 29 11.5 36 10.1
Trade or technical training 52 20.6 54 15.2
University degree (>13 years) 66 26.2 94 26.4
Did not want to disclose 27 10.7 45 12.6
Ethnicity
White 242 96.0 347 97.5
Asian / Asian British 6 2.4 1 0.3
Did not want to disclose 4 1.6 8 2.3
IMD quintile
1 (least deprived) 53 21.0 71 19.9
2 36 14.3 54 15.2
3 26 10.3 55 15.4
4 98 38.9 141 39.6
5 (most deprived) 39 15.5 35 9.8
Living arrangements
Not alone 185 73.4 273 76.7
Alone 63 25.0 75 21.1
Did not want to disclose 4 1.6 8 2.2
Country
England 64 25.4 50 14.0
Northern Ireland 16 6.3 33 9.3
Scotland 74 29.4 114 32.0
Wales 98 38.9 159 44.7
Time since breast cancer diagnosis
1–5 years - - 134 37.6
5–10 years - - 113 31.7
10–15 years - - 88 24.7
15–20 years - - 16 4.5
> 20 years - - 5 1.4
Breast cancer treatments
Surgery - - 351 98.6
Lumpectomy - - 226 63.5
Mastectomy - - 125 35.1
Reconstruction - - 44 12.4
Radiotherapy - - 283 79.5
Chemotherapy - - 145 40.7
Hormone therapy - - 175 49.2
Immunotherapy - - 6 1.7
Stage at diagnosis
Localised to the breast - - 195 54.8
Regional metastases - - 153 43.0
J Cancer Surviv
Breast cancer survivors had non-significantly higher odds
of probable anxiety (HADS-anxiety score ≥ 11) than controls
(adjusted odds ratio (aOR) = 1.37, 0.95–1.97; Table 4).
However there was strong evidence of a difference when a
more sensitive threshold (score ≥ 8, ‘borderline/probable anx-
iety’) was used (aOR = 1.46, 1.14–1.88). There were no dif-
ferences in odds of probable depression (aOR = 1.17, 0.52–
2.67).
Determinants of QoL and symptoms of anxiety and
depression in breast cancer survivors
Figure 2 shows the variation of the summary scores of QoL,
anxiety, and depression, by socio-demographic and clinical
variables. For both generic and cancer-specific domains of
QoL, younger age at questionnaire response, chemotherapy
treatment, lymph node involvement, and not being menopaus-
al at diagnosis were all associated with poorer QoL. The as-
sociations remained statistically significant after adjusting for
socio-demographic variables, except for the effect of meno-
pause on the generic domains of QoL, which was no longer
statistically significant (Supplementary Tables 2, 3, 4 and 5).
The effects of chemotherapy, menopausal status, and stage at
diagnosis were no longer statistically significant after further
adjusting for treatment variables. Higher education degree and
not living alone were associatedwith better QoL for the cancer
specific domains, but only education remained significantly
associated after adjusting for socio-demographic and clinical
variables (Supplementary Tables 6 and 7). Increasing time
since diagnosis resulted in better QoL for the generic domains,
while for the cancer-specific domains no variation on QoL
was noted by proximity to diagnosis.
For individual QoL domains, in fully adjusted models,
older women (≥ 70 years) had significantly fewer negative
feelings, cognitive problems, sexual dysfunction, avoidance,
financial problems, and family- and recurrence-related distress
compared with younger breast cancer survivors (< 60 years)
(Supplementary Table 2). Pre-menopausal women at diagno-
sis reported more negative feelings and avoidance compared
with those who were menopausal (Supplementary Table 3).
Women treated with chemotherapy had more cognitive prob-
lems, and appearance and recurrence concerns compared with
those that did not receive chemotherapy (Supplementary
Table 4). Compared with women diagnosed with localised
disease, those with lymph node or distant metastases reported
more pain and sexual dysfunction (Supplementary Table 5).
Women living alone reported more concerns with cancer re-
currence, while women with higher education had
Table 1 (continued)
No history of cancer (N = 252) Breast cancer survivors (N = 356)
N % N %
Distant metastases - - 2 0.6
Unknown - - 6 1.7
Time since last treatment for breast cancer
Under treatment - - 3 0.8
< 12 months - - 2 0.6
Between 1 and 5 years - - 124 34.8
More than 5 years - - 219 61.5
Does not know - - 8 2.2
Disease status at questionnaire response
In remission - - 322 90.4
Active disease - - 7 2.0
Does not know 27 7.6
Menopausal status
Menopausal at breast cancer diagnosis - - 244 68.5
Became menopausal during breast cancer treatment - - 72 20.2
Not menopausal - - 33 9.3
Unknown - - 7 2.0
*Information on age at questionnaire completion, time since breast cancer diagnosis, practice postcode IMD quintile, and country were obtained from the
electronic health records of the participating patients. Information on education, ethnicity, living arrangements, treatments for breast cancer, stage at
diagnosis, time since last treatment for breast cancer, and disease and menopausal status were collected directly from the patients using a self-reported
questionnaire
§Proportion may not add to 100% due to rounding
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significantly less pain and distress related to their family mem-
bers getting cancer (Supplementary Tables 6 and 7).
Anxiety and depression were lower in women ≥ 70 years
old, compared with those < 60 years, and this remained sig-
nificant after control for confounding. Anxiety was also sig-
nificantly increased in women treated with chemotherapy and
women not menopausal at diagnosis, but only the latter
remained statistically significant upon further adjustments.
Discussion
Breast cancer survivors had more cognitive problems, sexual
dysfunction, fatigue, and borderline to abnormal anxiety
symptoms than women who did not have cancer. The
increased risk was driven by exposure to chemotherapy and
more advanced disease at diagnosis. Among breast cancer
survivors, younger age, no higher education degree, pre-
menopausal status and more advanced disease at diagnosis,
and treatment with chemotherapy were all associated with
poorer QoL. Younger age was also associated with increased
anxiety and depressive symptoms.
This study has several strengths. We uniquely combined the
strengths of routinely collected electronic health records data,
enabling us to identify a large population-based sample of breast
cancer survivors and controls, with direct and targeted data col-
lection using validated instruments. We selected patients from
the CPRDGOLD primary care database, which is representative
of the UK population in terms of age, sex, and ethnicity [28].
Matching groups by primary care practice and age is likely to
Table 2 Quality of life anxiety and depressive symptoms, in breast cancer survivors and in women who never had cancer
Women with no history of cancer (N = 252) Women with history of breast cancer (N = 356)
No. (No.
imputed*)
Mean
score
SD Range %
Floor¶
%
Ceiling¶
No. (No.
imputed*)
Mean
score
SD Range %
Floor
%
Ceiling
Quality of life in adult
cancer survivors§
Generic
Negative feelings 251 (7) 11.0 4.9 4–26 3.7 0.0 346 (22) 11.6 5.3 4–28 4.3 0.3
Positive feelings§ 250 (5) 21.1 5.4 7–28 0.0 9.9 347 (18) 20.8 5.7 7–28 0.0 10.7
Cognitive
problems
251 (4) 10.5 4.7 4–28 6.2 0.8 350 (19) 11.7 5.3 4–27 4.9 0.0
Physical pain 249 (4) 11.1 6.5 4–28 12.0 0.8 347 (19) 11.2 6.2 4–28 9.5 1.4
Sexual
interest/function
227 (8) 12.0 6.4 4–28 13.2 2.7 330 (27) 13.6 7.2 4–28 13.0 4.9
Fatigue/Energy 251 (1) 12.3 4.8 4–24 4.1 0.0 350 (11) 13.3 5.0 4–25 3.7 0.0
Social avoidance 251 (21) 9.8 5.6 4–28 17.3 0.4 347 (45) 9.9 5.8 4–28 24.8 0.6
Summary ‡ 226 (0) 75.7 27.7 28–157 – – 318 (0) 80.4 29.0 29–162 - -
Cancer-specific
Financial problems - - - - - - 351 (9) 7.3 5.2 4–28 46.2 0.6
Distress related to
family
- - - - - - 352 (4) 12.3 7.5 4–28 2.6 7.8
Appearance
concerns
- - - - - - 350 (12) 9.4 5.9 4–28 20.2 4.8
Distress over
recurrence
- - - - - - 351 (8) 13.9 6.9 4–28 27.4 0.9
Summary - - - - - - 350 (0) 42.7 19.6 16–106 7.1 2.9
Benefits of cancer§ - - - - - - 348 (7) 17.0 6.6 4–28 - -
Hospital Anxiety and
Depression Scale
Anxiety 248 (7) 6.4 4.1 0–20 5.0 0.4 351 (4) 6.8 4.6 0–20 8.0 0.3
Depression 249 (4) 3.6 3.3 0–17 14.5 0.0 352 (3) 3.6 3.6 0–19 17.6 0.0
SD standard deviation
*Number of patient with score imputed. When one item was missing out of the four items in the domain, we imputed this item with the arithmetic mean
of the values in the other three items. Mean domain score was not calculated for patients that did not reply to two or more items in a domain
§Higher scores represent poorer QoL, except for the domains ‘positive feelings’ and ‘benefits of cancer’
‡Calculated as the sum of all domain scores except for positive feelings
¶ Proportion of patients with domain scores at the extreme low (floor) or high (ceiling) of the distribution
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1,711 women with no history of cancer 
(except for non-melanoma skin cancer)
Matched *
1,018 women with history of breast cancer
eligible for the study and invited to 
participate
6 replied but refused to participate
659 did not reply
1,116 women with history of breast cancer
potentially eligible for the study
98 women (8.78%) excluded because the 
GP considered the patient unable to
complete a self-reported questionnaire ¥
236 women (13.79%) excluded because
the GP considered the patient unable to 
complete a self-reported questionnaire ¥
1,475 women with no history of cancer 
eligible for the study and invited to 
participate
6 replied but refused to participate
1,217 did not reply
356 women with history of breast 
cancer included in the study
(34.7% of those eligible)
252 women with no history of cancer
included in the study
(17.1% of those eligible)
40 primary care practices accepted to participate in the study
Fig. 1 Flowchart of patient recruitment. CPRD Clinical Practice
Research Datalink. *Women in the comparison group included a
random sample of women with no history of cancer that had the same
age distribution as the breast cancer survivors in the primary care practice
(frequency matching). Initially matching occurred on a ratio of one case
to one control.We later revised this to one case to two controls, to account
for lower participation rate in the control group. ¥Exclusion criteria
included patients with dementia, terminally ill, or with another cancer
diagnosis. GPs also excluded patients who were not able to complete
questionnaires in English, or who had died or transferred out of their
practice recently
Table 3 Comparison of patient reported outcomes between breast cancer survivors and controls, by chemotherapy and stage at diagnosis
Women with no history of
cancer
Women with a history of breast cancer
All Treated with chemotherapy Stage of disease at diagnosis
No
chemotherapy
Chemotherapy Localised Advanced
β* 95%CI β* 95%CI β* 95%CI β* 95%CI β* 95%CI
QLACS:
Generic domains
Negative feelings Ref. 0.7 − 0.1–1.4 0.1 − 0.7–1.0 1.4 0.2–2.6 0.2 − 0.6–1.0 1.4 0.2–2.5
Positive feelings Ref. − 0.3 − 1.2–0.6 − 0.2 − 1.2–0.8 − 0.6 − 1.9–0.7 − 0.2 − 1.2–0.7 − 0.5 − 1.8–0.8
Cognitive
problems
Ref. 1.4 0.4–2.3 0.6 − 0.3–1.5 2.6 1.3–3.8 0.9 − 0.1–1.9 2.0 0.9–3.2
Pain Ref. 0.2 − 1.1–1.6 − 0.2 − 1.6–1.2 0.9 − 0.8–2.6 − 0.6 − 2.0–0.8 1.2 − 0.4–2.8
Sexual function Ref. 1.7 0.4–3.0 1.2 0.0–2.4 2.5 0.6–4.3 0.8 − 0.5–2.1 2.9 1.3–4.6
Energy/Fatigue Ref. 1.3 0.4–2.2 1.2 0.2–2.1 1.5 0.4–2.7 1.0 0.0–2.0 1.7 0.6–2.9
Avoidance Ref. 0.1 − 1.0–1.2 − 0.3 − 1.5–0.9 0.8 − 0.6–2.2 − 0.2 − 1.2–0.8 0.6 − 0.9–2.2
Summary Ref. 5.9 − 0.2–11.8 2.3 − 3.6–8.2 11.0 3.6–18.3 1.8 − 4.1–7.7 11.1 3.8–18.3
HADS
Anxiety Ref. 0.5 − 0.1–1.0 0.1 − 0.6–0.8 1.1 0.2–2.0 0.4 − 0.3–1.0 0.8 − 0.2–1.7
Depression Ref. 0.1 − 0.5–0.7 0.1 − 0.6–0.7 0.2 − 0.7–1.0 0.0 − 0.7–0.7 0.3 − 0.5–1.0
*Beta scores represent the difference between the scores of breast cancer survivors and the scores of the women in the comparison group. These were
adjusted for adjusted for age, education, and IMD quintile. Positive beta scores indicate more problems (poorer QoL) in breast cancer survivors
HADS Hospital Anxiety and Depression Scale, QLACS Quality of Life in Adult Cancer Survivors, 95%CI 95% confidence interval
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have accounted for measurable and some immeasurable con-
founding; we further collected data for education, ethnicity, and
a proxy of social support, which are known to be imperfectly
recorded in the patients’ clinical records, and this allowed us to
account for these variables in analyses. The validity of the tools
used to assess outcomes has been established [29–32]. Finally,
our study was sufficiently powered for the main comparison of
QoL between breast cancer survivors and controls, as we exceed
the target sample size. However, this study also has limitations.
Themajor threat to the validity of our results comes from the low
participation rate (35% in the breast cancer survivors group; 17%
in the control group). Even though this participation rate overall
surpassed our estimate at study design of 20%, and is similar to
participation rates in QoL studies in cancer survivors in the UK
[33], we cannot rule out selection bias where healthier women,
both physically and psychologically, are more likely to partici-
pate. Our final sample overwhelmingly included white women,
without distant metastases, and not undergoing further treatment
for breast cancer (excluding tamoxifen), and thus, our results
may not be generalisable to all breast cancer survivors. Another
limitation is that clinical information was self-reported, which
may have led to some information bias, but we expect this to
have minor impact on our results. The QLACS was well accept-
ed but some missing responses were observed, most often for
items related to sexual interest and function, and social avoid-
ance; our proportion of missing data was similar to another study
assessing QoL with QLACS in cancer survivors in the UK [29].
It is unclear whether the missing responses were related to values
themselves, but it is plausible that women with sexual problems
may not feel comfortable in reporting their sexual function, de-
spite the anonymous nature of the data collection. In addition,
older women may have fewer opportunities to engage in
partnered sexual activity (e.g. widowed, erectile dysfunction in
partners), and therefore consider these items not applicable to
them. For the social avoidance domain, one itemwas particularly
more often not replied—related to being ‘reluctant to start new
relationships’. We think this itemmight have been interpreted by
the patients as starting new romantic relationships, and thus left
blank due to no applicability. Lastly, residual confounding may
be present in our results, particularly for socio-economic status,
which we measured by proxy of education and quintile of Index
of Multiple Deprivation.
Similarly to studies conducted in the UK and elsewhere
[11, 21, 34–36], our results show that only a subgroup of
breast cancer survivors have poor QoL. While previous stud-
ies in the UK focused in survivors > 5 years after diagnosis,
we uniquely included patients from the 1st anniversary of their
cancer diagnosis and identified the characteristics associated
with poorer QoL; these can be used to inform allocation of
resources, but caution must be taken to not overgeneralise our
results. For example, Dialla et al. [37] reported that disease
progression was among the most important determinants of
poor QoL among younger women; we had very few patients
with active disease, and therefore were not able to assess this.
Our results were also consistent with previous studies address-
ing the links between breast cancer survivorship and sexual
dysfunction, fatigue, and exposure to chemotherapy and
worse cognitive function [38–42]. The poorer QoL andmental
health in younger breast cancer survivors is likely to be ex-
plained by specific concerns that may not be applicable to
older women, such as fertility and body image issues and/or
the impact of their possible death for their young offspring
Table 4 Unadjusted and adjusted associations between breast cancer survivorship and anxiety and depression categories
Anxiety Depression
Cut-off ≥ 11 for
caseness (probable
anxiety)
Cut-off ≥ 8 for caseness
(borderline/probable anxiety)
Cut-off ≥ 11 for caseness
(probable depression)
Cut-off ≥ 8 for caseness
(borderline/probable depression)
No. of cases
(%)
OR 95%CI No. of cases
(%)
OR 95%CI No. of cases
(%)
OR 95%CI No. of cases
(%)
OR 95%CI
Unadjusted
No cancer 44 (17.4) Ref 87 (35.1) Ref 9 (3.6) Ref 38 (15.3) Ref
Breast
cancer
80 (22.8) 1.37 0.95–1.97 155 (44.2) 1.46 1.14–1.88 17 (4.8) 1.35 0.68–2.68 54 (15.3) 1.00 0.72–1.41
Adjusted*
No cancer 39 (17.7) Ref 79 (35.8) Ref 8 (3.6) Ref 33 (14.9) Ref
Breast
cancer
70 (22.7) 1.41 0.93–2.13 139 (45.1) 1.48 1.16–1.89 12 (3.9) 1.17 0.52–2.67 46 (14.9) 1.07 0.77–1.50
*Adjusted for age, education, and IMD quintile in multivariate analyses. The number of patients in multivariate analyses varies due to missing data for
education level
OR odds ratio, 95%CI 95% confidence interval
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[10, 16, 17, 43]. Post-traumatic growth, the phenomenon
in which women appreciate life more after a traumatic
event [44], is likely explain the better QoL of older
women as they also had the highest scores for positive
feelings and benefits of cancer.
Public health interventions to improve QoL ought to be com-
prehensive, including risk reducing and reactive strategies.
Studies have reported that eight in 10 women with breast cancer
in the UK were not told about the potential long-term impact of
the cancer on their mental health [45], and 41% of women re-
ported not having received the professional support needed to
cope with the long-term consequences of their disease [46].
Patient education for prevention and early detection of
treatment-related sequelae should start as early as possible (in
the pre-operative period), focusing on both physical and mental
health [47, 48]. When survivors report issues related to QoL,
interventions should be based in evidence. A review of system-
atic reviews of non-pharmacological interventions to improve
Age group (ref= 35-59 years)
60-69 years
70-81 years
Higher education (ref= no)
Yes
Living arrangements (ref= not alone)
Alone
Type of surgery (ref= lumpectomy)
Mastectomy
Breast reconstruction (ref= no)
Yes
Radiotherapy (ref= no)
Yes
Chemotherapy (ref= no)
Yes
Hormone therapy (ref= no)
Yes
Stage at diagnosis (ref= localised)
Advanced
Menopausal (ref= yes)
Not menopausal
Time since diagnosis (ref= 1-5 yrs)
5-10 years
>10 years
ID
Study
-4.50 (-13.00, 3.90)
-12.60 (-22.50, -2.70)
-6.30 (-14.50, 2.00)
-5.90 (-15.00, 3.20)
0.90 (-6.30, 8.10)
8.10 (-1.00, 17.20)
6.40 (-0.50, 13.40)
8.70 (3.80, 13.70)
2.20 (-4.00, 8.40)
8.60 (2.40, 14.80)
-8.30 (-14.60, -1.90)
-4.88 (-10.71, 0.95)
-10.04 (-15.35, -4.74)
Beta (95% CI)
118
105
87
58
115
40
257
134
156
142
101
97
100
No
81.7
73.6
76.5
75.7
81.5
87.4
81.6
85.4
81.5
85.3
86.0
81.5
81.1
Mean
28.7
27.0
25.9
28.3
31.2
30.0
28.5
29.2
29.7
30.1
28.2
27.1
29.8
SD
Better QoL  Poorer QoL 
0-20 -10 10 20
Generic domains of QoL
Age group (ref= 35-59 years)
60-69 years
70-81 years
Higher education (ref= no)
Yes
Living arrangements (ref= not alone)
Alone
Type of surgery (ref= lumpectomy)
Mastectomy
Breast reconstruction (ref= no)
Yes
Radiotherapy (ref= no)
Yes
Chemotherapy (ref= no)
Yes
Hormone therapy (ref= no)
Yes
Stage at diagnosis (ref= localised)
Advanced
Menopausal (ref= yes)
Not menopausal
Time since diagnosis (ref= 1-5 yrs)
5-10 years
>10 years
ID
Study
-4.90 (-10.70, 0.90)
-10.00 (-15.30, -4.70)
-5.40 (-10.30, -0.50)
-5.40 (-9.80, -1.10)
4.40 (-0.60, 9.40)
6.30 (0.30, 12.30)
2.50 (-1.70, 6.60)
10.90 (7.10, 14.70)
2.40 (-1.60, 6.40)
6.30 (1.60, 11.00)
-5.60 (-10.10, -1.20)
0.17 (-4.06, 4.40)
1.42 (-4.18, 7.03)
Beta (95% CI)
129
119
93
72
124
44
280
143
171
154
110
112
105
No
43.1
37.9
39.1
38.8
45.9
48.3
43.2
49.2
44.0
46.5
46.6
42.4
43.7
Mean
18.2
18.3
17.1
19.5
21.4
22.5
20.0
20.8
21.2
21.1
20.7
20.2
18.5
SD
Better QoL  Poorer QoL 
0-20 -10 10 20
Cancer specific domains of QoL
Age group (ref= 35-59 years)
60-69 years
70-81 years
Higher education (ref= no)
Yes
Living arrangements (ref= not alone)
Alone
Type of surgery (ref= lumpectomy)
Mastectomy
Breast reconstruction (ref= no)
Yes
Radiotherapy (ref= no)
Yes
Chemotherapy (ref= no)
Yes
Hormone therapy (ref= no)
Yes
Stage at diagnosis (ref= localised)
Advanced
Menopausal (ref= yes)
Not menopausal
Time since diagnosis (ref= 1-5 yrs)
5-10 years
>10 years
ID
Study
-1.20 (-2.50, 0.10)
-1.90 (-3.20, -0.50)
0.40 (-1.00, 1.80)
-0.70 (-2.00, 0.50)
0.80 (-0.40, 1.90)
1.20 (-0.10, 2.50)
-0.10 (-1.10, 1.00)
1.10 (0.20, 2.00)
-0.10 (-1.30, 1.20)
0.50 (-0.70, 1.70)
-1.70 (-2.90, -0.50)
-0.32 (-1.26, 0.62)
0.23 (-1.11, 1.57)
Beta (95% CI)
129
119
93
72
122
44
282
145
174
155
242
112
106
No
6.7
6.0
7.2
6.3
7.3
7.9
6.8
7.5
6.8
7.2
6.3
6.5
7.1
Mean
4.7
4.5
4.0
4.6
4.6
4.7
4.6
4.3
4.4
4.7
4.5
4.3
4.5
SD
Fewer symptoms  More symptoms 
0-5 -4 -3 -2 -1 1 2 3 4 5
Anxiety
Age group (ref= 35-59 years)
60-69 years
70-81 years
Higher education (ref= no)
Yes
Living arrangements (ref= not alone)
Alone
Type of surgery (ref= lumpectomy)
Mastectomy
Radiotherapy (ref= no)
Yes
Chemotherapy (ref= no)
Yes
Hormone therapy (ref= no)
Yes
Stage at diagnosis (ref= localised)
Advanced
Menopausal (ref= yes)
Not menopausal
Time since diagnosis (ref= 1-5 yrs)
5-10 years
>10 years
ID
Study
-0.50 (-1.40, 0.40)
-0.80 (-2.10, 0.40)
-0.80 (-1.60, 0.10)
-0.20 (-1.30, 0.80)
0.40 (-0.60, 1.30)
-0.10 (-1.00, 0.70)
0.20 (-0.60, 0.90)
0.10 (-0.80, 0.90)
0.50 (-0.40, 1.30)
-0.40 (-1.40, 0.60)
-0.38 (-1.07, 0.31)
0.05 (-0.97, 1.06)
Beta (95% CI)
129
120
94
73
122
282
145
174
155
109
112
106
No
3.6
3.3
3.1
3.5
3.9
3.6
3.7
3.7
3.9
3.9
3.4
3.8
Mean
3.4
3.6
3.0
3.5
3.8
3.6
3.5
3.6
3.8
3.7
3.4
3.5
SD
Fewer symptoms  More symptoms 
0-5 -4 -3 -2 -1 1 2 3 4 5
Depression
Fig. 2 Quality of life, and anxiety and depressive symptoms, in breast cancer survivors, by socio-demographic, clinical, and treatment characteristics
(N = 356)
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QoL in breast cancer survivors found that exercise interventions,
yoga, and other physical activity-related interventions, cognitive-
behavioural therapy, and mindfulness-based stress reduction all
were beneficial for the patients’ quality of life [49]. However,
access to these interventions depends largely on availably, which
is known to be currently insufficient [46, 50]. Where these are
available, raising awareness about the services locally available
to patients, and how to access them, cannot be overlooked (e.g.
Breast Cancer Now, a UK-based charity, has created a course
tailored to breast cancer survivors, which was found to improve
patients’ HRQoL, emotional wellbeing, and self-management
measures [51]). On the pharmacological side, it is also important
to raise awareness among health care professionals of the impor-
tance of addressing issues such as sexual function, which is a
topic often poorly communicated in clinics [52, 53].
Future research on the QoL of breast cancer survivors
in the UK should focus on the barriers patients face when
accessing interventions aimed at preventing declines in
QoL in the long term, as well as assessing time trends
in QoL, as it is unclear if modern treatments yield better
QoL. Evidence on non-pharmacological interventions for
QoL in cancer survivors tended to include patients in the
first few years of their survivorship journey [49]; future
studies need to establish the efficacy of interventions in
long-term survivors. Studies are also needed to assess if
women diagnosed with breast carcinomas in situ have
differ in terms of QoL from both breast cancer survivors
and women who did not have cancer, as these tumours are
treated similarly to early stage breast cancer.
In conclusion, breast cancer survivors in the UK reported
higher risk of problems with cognition, sexual function, fa-
tigue, and borderline/probable anxiety, particularly where
their cancer was advanced and/or treated with chemotherapy.
This information can be used to tailor increased surveillance
for mental health and QoL issues in these groups.
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